《国家基层糖尿病防治管理指南(2022)》中医药内容解读与比较  

Interpretation and Comparison of the Contents of Chinese Medicine in National Guidelines for the Prevention and Control of Diabetes in Primary Care(2022)

作　　者：赵能江[1] 杨叔禹[1] 孙文杰 李博[1] 贾丽艳 闫冰[1] ZHAO Neng-jiang;YANG Shu-yu;SUN Wen-jie;LI Bo;JIA Li-yan;YAN Bin(Department of Traditional Chinese Medicine Studio,The First Affiliated Hospital of Xiamen University,Fujian,361003)

机构地区：[1]厦门大学附属第一医院中医工作室,福建361003

出　　处：《中国中西医结合杂志》2023年第2期232-235,共4页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家中医药管理局委托项目(No.2021-141);福建省名中医工作室项目(No.2018-216);福建省中医药科研项目(No.2021zyg178)。

摘　　要：“中西医并重”是我国糖尿病防治的重要策略和方针。为规范基层糖尿病诊疗,2022年3月中华医学会糖尿病学分会,国家基层糖尿病防治管理办公室共同发布了《国家基层糖尿病防治管理指南(2022)》,此次更新首次增加了糖尿病的中医药防治内容。笔者结合《中国2型糖尿病防治指南(2020)》,对指南中医药纳入背景和要点进行解读和对比分析,为临床应用提供参考。Equal importance should be placed on both Chinese medicine(CM) and Western medicine and this is an important strategy and guideline for the prevention and treatment of diabetes in China. In order to standardize the diabetes prevention and treatment in primary medical care,Chinese Diabetes Society and National Office for Primary Diabetes Care issued the "National guidelines for the prevention and control of diabetes in primary care(2022)". One of the highlights of this update is adds the content of CM to prevention and treatment of diabetes for the first time. This article will interpret the background and core content of CM in the guidelines,and analyzed in combination with the “Chinese guidelines for the prevention and treatment of type 2diabetes(2020)”,in order to provide reference for clinical application.

关 键 词：糖尿病 基层 中医药 指南解读 

分 类 号：R587.1[医药卫生—内分泌]